ArticleCellular oncology (Dordrecht, Netherlands)2023

Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma.

Zhen Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.